61 completed, 20 active not recruiting, 15 recruiting, 12 terminated. 122 Phase 3, 6 Phase 2.
Follow Carcinoma, Renal Cell: new trials by email Literature Review of Carcinoma, Renal Cell trials Research Report on Carcinoma, Renal Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-10-28 |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| Lu-177 PSMA Treatment in Cell Renal Carcinoma Lu-177 PSMA-617 - Metastatic Renal Cancer | Phase 3 | Not yet recruiting | Ankara University | 20 | 2026-05-01 | 2026-02-27 |
| A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) Belzutifan, Zanzalintinib, Placebo - Carcinoma, Renal Cell | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 758 | 2026-04-09 | 2026-10-29 |
| Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC 177Lu-TLX250 - ccRCC, Renal Cell Carcinoma (Kidney Cancer) | Phase 3 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 40 | 2026-03-25 | 2026-04-01 |
| A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) Belzutifan, Zanzalintinib, Cabozantinib - Renal Cell Carcinoma | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 904 | 2025-11-26 | 2026-08-03 |
| R.E.C.K vs Exparel in Robotic Nephrectomy Ropivacaine HCL, Exparel, Epinephrine - Renal Carcinoma, Nephrectomy / Methods | Phase 3 | Recruiting | Wake Forest University Health Sciences | 170 | 2025-11-14 | 2026-07-13 |
| Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC piflufolastat F 18 - Clear Cell Renal Cell Carcinoma | Phase 2 / Phase 3 | Withdrawn | Lantheus Medical Imaging | 2025-11-01 | 2025-12-10 | |
| A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI Vorolanib Tablets+Everolimus, Sunitinib - Renal Cell Carcinoma (RCC) | Phase 3 | Not yet recruiting | Peking University Cancer Hospital & Institute | 116 | 2025-09-25 | 2025-09-10 |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer Pembrolizumab, Tivozanib, Biospecimen Collection - Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC) | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1040 | 2025-03-14 | 2026-11-03 |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 3 | Active not recruiting | NRG Oncology | 274 | 2024-12-12 | 2026-09-14 |
| 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study 89Zr-TLX250 PET/CT - Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 82 | 2024-11-06 | 2024-12-27 |
| Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study) Stereotactic body radiotherapy (SBRT), axitinib ± immune checkpoint inhibitors (ICIs), lenvatinib ± ICIs, cabozantinib ± ICIs, sunitinib and pazopanib - Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic | Phase 3 | Recruiting | Sun Yat-sen University | 252 | 2024-09-18 | 2026-01-15 |
| CARE1 Pragmatic Clinical Trial Nivolumab, Ipilimumab, Pembrolizumab - Metastatic Kidney Cancer, Metastatic Kidney Carcinoma | Phase 3 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 1250 | 2024-04-12 | 2025-01-16 |
| Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study Computed Tomography, Magnetic Resonance Imaging, Questionnaire Administration - Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 472 | 2023-12-27 | 2026-09-15 |
| DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers Alectinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-12-18 | 2025-11-24 |
| Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy Pembrolizumab, Placebo - Papillary Renal Cell Carcinoma | Phase 3 | Not yet recruiting | First Affiliated Hospital, Sun Yat-Sen University | 468 | 2023-12-01 | 2023-11-29 |
| Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma Axitinib plus Toripalimab, nephrectomy - Renal Cell Carcinoma, Neoadjuvant | Phase 3 | Recruiting | ZHOU FANGJIAN | 298 | 2023-04-19 | 2026-03-17 |
| Measuring Oncological Value of Exercise and Statin Guided physical exercise, Atorvastatin, Independent exercise - Prostate Cancer, Breast Cancer | Phase 3 | Recruiting | Tampere University Hospital | 240 | 2023-03-31 | 2025-06-27 |
Showing 20 of 122. Sign in to see all of them.
Kidney Neoplasms (36) · Neoplasms (13) · Neoplasm Metastasis (10) · Melanoma (6) · Carcinoma (5) · Parkinson Disease 4, Autosomal Dominant Lewy Body (5) · Breast Neoplasms (4) · Carcinoma, Hepatocellular (4) · Carcinoma, Non-Small-Cell Lung (4) · Prostatic Neoplasms (4) · Brain Neoplasms (3) · Recurrence (3) · Carcinoma, Transitional Cell (2) · Clear-cell metastatic renal cell carcinoma (2)
Adenocarcinoma (122) · Female Urogenital Diseases (122) · Female Urogenital Diseases and Pregnancy Complications (122) · Male Urogenital Diseases (122) · Neoplasms, Glandular and Epithelial (122) · Urogenital Diseases (122) · Urologic Diseases (122) · Neoplasms by Histologic Type (121) · Urogenital Neoplasms (121) · Urologic Neoplasms (121) · Kidney Diseases (120) · Neoplasms by Site (120) · Carcinoma (117) · Neoplasms (109) · Kidney Neoplasms (86)
Sunitinib (20) · Nivolumab (14) · Sorafenib (12) · pembrolizumab (12) · cabozantinib (11) · Interferon-alpha (10) · pazopanib (9) · Ipilimumab (8) · Bevacizumab (7) · Everolimus (7) · Magnetic Resonance Spectroscopy (7) · belzutifan (7) · Axitinib (6) · aldesleukin (6) · lenvatinib (6)
Merck Sharp & Dohme LLC (9) · National Cancer Institute (NCI) (7) · Bristol-Myers Squibb (6) · Hoffmann-La Roche (6) · Novartis Pharmaceuticals (5) · Pfizer (5) · Bayer (4) · Centre Leon Berard (4) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Alliance for Clinical Trials in Oncology (3) · Exelixis (3) · Heidelberg Pharma AG (3) · SWOG Cancer Research Network (3) · Telix Pharmaceuticals (Innovations) Pty Limited (3) · AVEO Pharmaceuticals, Inc. (2)
United States (71) · United Kingdom (48) · France (47) · Italy (47) · Canada (44) · Germany (42) · Spain (42) · Poland (37) · Australia (36) · Russia (32) · Czechia (31) · Netherlands (31) · Brazil (29) · South Korea (28) · Argentina (27)
Hein van Poppel, MD, PhD (2) · Sylvie Negrier, MD (2) · Andrew Scott, MD (1) · Arie Belldegrun, MD, FACS (1) · Arnaud Mejean, MD PhD (1) · Axel Bex (1) · Borje Ljungberg, MD, PhD (1) · Brian I. Rini, MD (1)
PMID 37146227, PMID 33526329, PMID 27238653, PMID 28410911, PMID 33058158, PMID 35304832, PMID 35383907, PMID 24338498, PMID 25577718, PMID 26457466, PMID 26685869, PMID 26702763, PMID 31992108, PMID 33947608, PMID 37526095, PMID 12810695, PMID 15102658, PMID 15961764, PMID 16965911, PMID 17140723, PMID 17189398, PMID 17215529, PMID 17215530, PMID 17538086, PMID 17551296, PMID 17868728, PMID 17932908, PMID 18602688, PMID 18653228, PMID 18794104, PMID 18840822, PMID 18936475, PMID 19451442, PMID 19757215, PMID 19850637, PMID 20082451, PMID 20085939, PMID 20104222, PMID 20153039, PMID 20194812, PMID 20368558, PMID 20399677, PMID 20651059, PMID 20881001, PMID 21186077, PMID 21858552, PMID 22209391, PMID 22297244, PMID 22342553, PMID 22480131
2016 (7), U10CA180820 (5), 2023 (4), 2017 (3), 2004 (2), 2008 (2), 2014 (2), 2018 (2), 2019 (2), U10CA021115 (2), U10CA031946 (2), U10CA180821 (2), U10CA180868 (2), 2005 (1), 2009 (1)